Business Wire

Patient Safety Movement Foundation to Co-Convene World Summit with the European Society of Anaesthesiology

Del

The Patient Safety Movement Foundation announced today that the European Society of Anaesthesiology (ESA) will co-convene the upcoming 6th Annual World Patient Safety, Science & Technology Summit, held for the first time in London, United Kingdom, on February 23 – 25, 2018.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171108006256/en/

Patient Safety Movement Foundation Founder, Joe Kiani, and European Society of Anaesthesiologists Pr ...

Patient Safety Movement Foundation Founder, Joe Kiani, and European Society of Anaesthesiologists President, Dr. Zeev Goldik, partner to co-convene 2018 World Patient Safety, Science & Technology Summit (Photo: Business Wire)

The World Patient Safety Summit is an impactful meeting where experts, patient advocates, and leaders from across the health care industry come together to discuss challenges, innovative new programs and best practices to prevent hospital errors and act to increase patient safety. Last year, more than 3,500 hospitals from 43 countries across the globe made commitments to the Patient Safety Movement Foundation to save more than 69,519 lives.

“We are delighted to be co-convening our annual summit with the European Society of Anaesthesiology,” said Joe Kiani, Founder of the Patient Safety Movement Foundation. “Patient safety is a critical challenge across the globe that impacts millions. Working hand in hand with leading medical societies, like the ESA, allows us to bring our message and our actionable patient safety solutions to save more people around the world.”

The European Society of Anaesthesiology (ESA) is the leading European Organization for Anaesthesia, Critical Care, Pain and Perioperative Medicine. The mission of the ESA is to aim for the highest standards of practice and safety in anaesthesia, perioperative medicine, intensive care, emergency medicine and pain treatment through education, research and professional development throughout Europe. The 2010 ESA-EBA Helsinki Declaration on Patient Safety in Anaesthesiology* was written to respond to preventable perioperative patient harm in surgery. It has been widely recognized globally as a practical framework for improving perioperative patient safety and has been signed by all European National Anaesthesiologists Societies and many international societies.

“Anaesthesiology shares responsibility for quality and safety in Anaesthesia, Intensive Care, Emergency Medicine and Pain Medicine, including the whole perioperative process and also in many other situations inside and outside the hospital where patients are at their most vulnerable,” says ESA President, Dr. Zeev Goldik. “The quality of care of our patients can only be reinforced and improved by ESA and the Patient Safety Movement joining forces.”

The 6th Annual World Patient Safety, Science & Technology Summit is organized with the support of the United Kingdom’s Secretary of State for Health, the Rt. Hon. Jeremy Hunt MP. The 2018 Summit will bring international hospital leaders, medical and information technology companies, the patient advocacy community, public policy makers and government officials together to discuss solutions to the leading challenges that cause preventable patient deaths in hospitals across the world. The Summit will feature keynote addresses from leading political figures and patient safety experts, plenary sessions with healthcare luminaries, members of the press and patient advocates, as well as announcements from organizations who have made their own commitments to reach the Patient Safety Movement Foundation’s goal of ZERO preventable deaths by 2020.

* Helsinki Declaration on Patient Safety in Anaesthesiology
Mellin-Olsen, Jannicke; Staender, Sven; Whitaker, David K; Smith, Andrew F
European Journal of Anaesthesiology: - July 2010 - Volume 27 - Issue 7 - p 592–597
doi: 10.1097/EJA.0b013e32833b1adf
http://journals.lww.com/ejanaesthesiology/Fulltext/2010/07000/The_Helsinki_Declaration_on_Patient_Safety_in.3.aspx

About Patient Safety Movement Foundation:

More than 200,000 people die every year in U.S. hospitals and 3 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to 0 by 2020 (0X2020). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems with actionable solutions for patient safety. The Foundation also convenes the World Patient Safety, Science and Technology Summit. The Summit brings together some of the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.

Contact information

Patient Safety Movement Foundation
Tanya Lyon, +1 (949) 351-2858
tanya.lyon@patientsafetymovement.org

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 13:55Pressemelding

Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 13:15Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk

Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 12:57Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl

Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation16.11.2018 08:00Pressemelding

Dimension Data, the USD 8 billion global technology integrator and managed services provider, today announced that its Global Delivery Centre (GDC) in Prague has won the 2018 ABSL Diamond award for Business Innovation. The main purpose of this centre is to provide innovative, global service delivery capabilities and deep technical expertise to support our clients. The ABSL Diamond awards recognise companies that implement innovative projects, enhancing their business and strengthening the position of the business services sector. Every year, the aim is to identify successful activities in this sector and promote best practices, ultimately encouraging and inspiring others to follow suit. The ABSL celebrates initiatives that push business services forward and stand out as exemplary projects. Bill Padfield, Group Chief Operating Officer for Transformation and Services at Dimension Data, said: “Winning another award for our Support Services is a fantastic achievement. This time the ABSL Di

FCC Grants LeoSat U.S. Market Access16.11.2018 06:00Pressemelding

LeoSat Enterprises, the dynamic young company which is launching a unique new data network comprised of a constellation of up to 108 low-earth-orbit communications satellites, has been awarded the authority by the U.S. Federal Communications Commission (FCC) to provide NGSO (non-geostationary satellite orbit) services in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005890/en/ LeoSat's Global Business Backbone in Space (Graphic: Business Wire) The increasing demand for business connectivity and with it, the need to move large quantities of data quickly and securely around the world, is fast outpacing the infrastructure in place to carry it. Existing networks are already carrying more than 1 Zeta Byte of traffic globally and this is set to grow exponentially. The FCC market access grant will allow LeoSat to address currently unmet demand for high-bandwidth, low-latency, high-security data transmissio

German Court Rules Huawei, ZTE Products Infringe AVC Patents16.11.2018 05:01Pressemelding

MPEG LA announced today that the District Court in Düsseldorf, Germany (“Landgericht Düsseldorf”) has ruled that Huawei Technologies Deutschland GmbH (“Huawei”) and ZTE Deutschland GmbH (“ZTE”) infringed patents of two patent holders in MPEG LA’s AVC Patent Portfolio License (“AVC License”) by using their technologies in mobile phones that implement the AVC/H.264 (MPEG-4 Part 10) Standard. The court also found that the license offered by the patent holders under those patents through the AVC License is fair, reasonable and nondiscriminatory. “The Landgericht Düsseldorf’s decision confirms the importance of respect for intellectual property, and offering everyone easy and affordable access to essential AVC technology under a single license is a cornerstone of the MPEG LA AVC License’s wide acceptance making that possible,” said Larry Horn, President and CEO of MPEG LA. “We continue to welcome Huawei and ZTE to join the nearly 2,000 Licensees who have entered into our AVC License.” Verdi